For people with severe deficiencies or who need rapid results, injections are often the best choice
Draw up the prescribed dose into the syringe, ensuring no air bubbles remain
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
Vegetarians and vegans may have low dietary intake since B12 comes almost entirely from animal products
If B12 deficiency is suspected, well confirm it with appropriate laboratory testing
Dihexa Is a synthetic oligopeptide drug that is being studied for its potential to treat neurodegenerative diseases, particularly Alzheimers disease
